Regulus Therapeutics Inc.

NasdaqCM:RGLS Stok Raporu

Piyasa değeri: US$102.8m

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Regulus Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Regulus Therapeutics has a total shareholder equity of $98.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $104.1M and $5.9M respectively.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranın/a
NakitUS$94.46m
EşitlikUS$98.18m
Toplam yükümlülüklerUS$5.94m
Toplam varlıklarUS$104.12m

Son finansal sağlık güncellemeleri

Recent updates

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

Sep 28
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

Regulus surges 15% after Phase 1 data for kidney disease candidate

Sep 12

Regulus Therapeutics GAAP loss per share narrows

Aug 11

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Oct 12
Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

The Read On Regulus Therapeutics

Aug 03

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Jun 09
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

May 03

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Mar 13
Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Mar 10
Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Regulus Therapeutics announces closing of $19.4M private placement

Dec 08

Regulus Therapeutics EPS beats by $0.17, beats on revenue

Nov 05

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RGLS's short term assets ($100.3M) exceed its short term liabilities ($5.3M).

Uzun Vadeli Yükümlülükler: RGLS's short term assets ($100.3M) exceed its long term liabilities ($675.0K).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RGLS is debt free.

Borcun Azaltılması: RGLS has no debt compared to 5 years ago when its debt to equity ratio was 308.3%.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RGLS has sufficient cash runway for more than a year based on its current free cash flow.

Tahmini Nakit Akışı: RGLS has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 5.3% each year.


Sağlıklı şirketleri keşfedin